CLEAR’s Patented Breakthrough: 3 Global Patents & 200 Dermatologists Validate Next-Gen Dandruff Solutions
SHANGHAI, April 30, 2025 /PRNewswire/ -- Recently, CLEAR, Unilever's premium professional anti-dandruff brand, held a grand launch event at TANK Shanghai, debuting its first-ever SCALPCEUTICALS PRO RANGE—a groundbreaking series born from over a decade of scientific research by 5 global labs and more than 200 dermatologists. This high-profile industry event not only marks a monumental breakthrough in CLEAR's 50-year journey...
Genocury Biotech Annouces Groundbreaking Advance in Relapsed/Refractory DLBCL Through Pioneering In Vivo CD19 CAR-T Therapy
Genocury launched the in vivo CD19 CAR-T therapy to reach the clinical stage, demonstrating exceptional safety, efficiency and durability. Results are attained without requiring lymphodepletion. SHENZHEN, China, April 30, 2025 /PRNewswire/ -- Genocury Biotech today revealed groundbreaking clinical data from its noval in vivo CD19 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), a notoriously aggressive blood...
J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics ‘JIN-A02’ and ‘JIN-001’ at AACR 2025
SEOUL, South Korea, April 30, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in anticancer and orphan drugs, announced its research findings for the next-generation EGFR-TKI therapeutic 'JIN-A02' (clinical Phase 1/2 results) and the ovarian cancer treatment candidate 'JIN-001' (preclinical results) at the American Association for Cancer Research (AACR) 2025, held in Chicago from April 25 to 30. In...
Alphamab Oncology Presented Preclinical Data on Two Novel Bispecific ADCs at the 2025 AACR Annual Meeting
SUZHOU, China, April 30, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting, which is held in Chicago, USA, from April 25 to 30, 2025. Title: JSKN021, an...
Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies
SAN FRANCISCO and SUZHOU, China, April 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced completion of the first patient dosing for IBI3020, its first-in-class dual-payload CEACAM5 ADC, in Phase 1 clinical trial...
Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Hong Kong
SHANGHAI, April 30, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the Department of Health of the Government of the Hong Kong Special Administrative Region, China, has officially approved the New Drug Application (NDA) for VELSIPITY® (etrasimod) for...
Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar
Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations Henlius to receive $31 million upfront, and up to $270 million in milestones SHANGHAI, April 29, 2025 /PRNewswire/ -- On April 29, 2025, Shanghai Henlius Biotech, Inc. (2696.HK) announced a licensing agreement with Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader...
PHASE Scientific Earns Prestigious Recognition at 2025 ASCCP Scientific Meeting for Innovation in Urine-Based HPV Screening
SAN DIEGO, April 29, 2025 /PRNewswire/ -- PHASE Scientific (PHASE) proudly announced a major milestone this week with its inaugural participation and award-winning presentation at the 2025 American Society for Colposcopy and Cervical Pathology (ASCCP) Annual Scientific Meeting — one of the foremost global events dedicated to advancing women's health. Held...
Metabolon Launches Microbiome Research Solution Combining New Microbiome Panel, Metagenomics Sequencing, and Multiomics Bioinformatics Tools
The combination of metagenomics and metabolomics data, integrated within an intuitive bioinformatics platform, enables deeper microbiome insights than possible with either approach individually MORRISVILLE, N.C., April 29, 2025 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life...
Continuity Biosciences Invests in PinPrint, Inc., Expanding into Aesthetic and Cosmetic Drug Delivery
BRADENTON, Fla., April 29, 2025 /PRNewswire/ -- Continuity Biosciences, LLC has made a strategic investment in PinPrint, Inc., a pioneering company in high-resolution 3D-printed microneedle technology. The investment expands Continuity's footprint beyond therapeutic delivery into aesthetic and cosmetic applications, enhancing long-term strategic value. PinPrint's 3D printing technology was developed by Joseph DeSimone, PhD, a...
